Literature DB >> 18587048

Disruption of Tsc2 in pancreatic beta cells induces beta cell mass expansion and improved glucose tolerance in a TORC1-dependent manner.

Latif Rachdi1, Norman Balcazar, Fernando Osorio-Duque, Lynda Elghazi, Aaron Weiss, Aaron Gould, Karen J Chang-Chen, Michael J Gambello, Ernesto Bernal-Mizrachi.   

Abstract

Regulation of pancreatic beta cell mass and function is a major determinant for the development of diabetes. Growth factors and nutrients are important regulators of beta cell mass and function. The signaling pathways by which these growth signals modulate these processes have not been completely elucidated. Tsc2 is an attractive candidate to modulate these processes, because it is a converging point for growth factor and nutrient signals. In these experiments, we generated mice with conditional deletion of Tsc2 in beta cells (betaTsc2(-/-)). These mice exhibited decreased glucose levels and hyperinsulinemia in the fasting and fed state. Improved glucose tolerance in these mice was observed as early as 4 weeks of age and was still present in 52-week-old mice. Deletion of Tsc2 in beta cells induced expansion of beta cell mass by increased proliferation and cell size. Rapamycin treatment reversed the metabolic changes in betaTsc2(-/-) mice by induction of insulin resistance and reduction of beta cell mass. The reduction of beta cell mass in betaTsc2(-/-) mice by inhibition of the mTOR/Raptor (TORC1) complex with rapamycin treatment suggests that TORC1 mediates proliferative and growth signals induced by deletion of Tsc2 in beta cells. These studies uncover a critical role for the Tsc2/mTOR pathway in regulation of beta cell mass and carbohydrate metabolism in vivo.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18587048      PMCID: PMC2453727          DOI: 10.1073/pnas.0803047105

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  35 in total

Review 1.  Life and death of the pancreatic beta cells.

Authors:  S Bonner-Weir
Journal:  Trends Endocrinol Metab       Date:  2000-11       Impact factor: 12.015

Review 2.  Clinical review 135: The importance of beta-cell failure in the development and progression of type 2 diabetes.

Authors:  S E Kahn
Journal:  J Clin Endocrinol Metab       Date:  2001-09       Impact factor: 5.958

3.  Affordable image analysis using NIH Image/ImageJ.

Authors:  V Girish; A Vijayalakshmi
Journal:  Indian J Cancer       Date:  2004 Jan-Mar       Impact factor: 1.224

4.  Tissue-specific insulin resistance in mice with mutations in the insulin receptor, IRS-1, and IRS-2.

Authors:  Y Kido; D J Burks; D Withers; J C Bruning; C R Kahn; M F White; D Accili
Journal:  J Clin Invest       Date:  2000-01       Impact factor: 14.808

5.  Activation of IRS-2-mediated signal transduction by IGF-1, but not TGF-alpha or EGF, augments pancreatic beta-cell proliferation.

Authors:  Melissa K Lingohr; Lorna M Dickson; Jill F McCuaig; Sigrun R Hugl; Daniel R Twardzik; Christopher J Rhodes
Journal:  Diabetes       Date:  2002-04       Impact factor: 9.461

6.  Generation of a conditional disruption of the Tsc2 gene.

Authors:  Omar Hernandez; Sharon Way; James McKenna; Michael J Gambello
Journal:  Genesis       Date:  2007-02       Impact factor: 2.487

7.  Islet beta cell expression of constitutively active Akt1/PKB alpha induces striking hypertrophy, hyperplasia, and hyperinsulinemia.

Authors:  E Bernal-Mizrachi; W Wen; S Stahlhut; C M Welling; M A Permutt
Journal:  J Clin Invest       Date:  2001-12       Impact factor: 14.808

8.  Protein kinase Czeta activation mediates glucagon-like peptide-1-induced pancreatic beta-cell proliferation.

Authors:  J Buteau; S Foisy; C J Rhodes; L Carpenter; T J Biden; M Prentki
Journal:  Diabetes       Date:  2001-10       Impact factor: 9.461

9.  beta-cell-specific deletion of the Igf1 receptor leads to hyperinsulinemia and glucose intolerance but does not alter beta-cell mass.

Authors:  R N Kulkarni; M Holzenberger; D Q Shih; U Ozcan; M Stoffel; M A Magnuson; C R Kahn
Journal:  Nat Genet       Date:  2002-04-01       Impact factor: 38.330

10.  mTOR interacts with raptor to form a nutrient-sensitive complex that signals to the cell growth machinery.

Authors:  Do-Hyung Kim; D D Sarbassov; Siraj M Ali; Jessie E King; Robert R Latek; Hediye Erdjument-Bromage; Paul Tempst; David M Sabatini
Journal:  Cell       Date:  2002-07-26       Impact factor: 41.582

View more
  89 in total

Review 1.  mTOR signaling in growth control and disease.

Authors:  Mathieu Laplante; David M Sabatini
Journal:  Cell       Date:  2012-04-13       Impact factor: 41.582

Review 2.  The role of mammalian target of rapamycin (mTOR) in the regulation of pancreatic β-cell mass: implications in the development of type-2 diabetes.

Authors:  Jianling Xie; Terence P Herbert
Journal:  Cell Mol Life Sci       Date:  2011-11-09       Impact factor: 9.261

Review 3.  Minireview: Meeting the demand for insulin: molecular mechanisms of adaptive postnatal beta-cell mass expansion.

Authors:  Mira M Sachdeva; Doris A Stoffers
Journal:  Mol Endocrinol       Date:  2009-02-05

4.  mTORC1 activation regulates beta-cell mass and proliferation by modulation of cyclin D2 synthesis and stability.

Authors:  Norman Balcazar; Aruna Sathyamurthy; Lynda Elghazi; Aaron Gould; Aaron Weiss; Ichiro Shiojima; Kenneth Walsh; Ernesto Bernal-Mizrachi
Journal:  J Biol Chem       Date:  2009-01-14       Impact factor: 5.157

5.  SAD-A and AMPK kinases: the "yin and yang" regulators of mTORC1 signaling in pancreatic β cells.

Authors:  Jia Nie; Xiao Han; Yuguang Shi
Journal:  Cell Cycle       Date:  2013-09-18       Impact factor: 4.534

6.  Automated quantification of pancreatic β-cell mass.

Authors:  Maria L Golson; William S Bush; Marcela Brissova
Journal:  Am J Physiol Endocrinol Metab       Date:  2014-04-22       Impact factor: 4.310

Review 7.  The mTOR Signaling Pathway in Myocardial Dysfunction in Type 2 Diabetes Mellitus.

Authors:  Tomohiro Suhara; Yuichi Baba; Briana K Shimada; Jason K Higa; Takashi Matsui
Journal:  Curr Diab Rep       Date:  2017-06       Impact factor: 4.810

Review 8.  Tuberous sclerosis complex, implication from a rare genetic disease to common cancer treatment.

Authors:  Ken Inoki; Kun-Liang Guan
Journal:  Hum Mol Genet       Date:  2009-04-15       Impact factor: 6.150

9.  Chronic rapamycin treatment causes glucose intolerance and hyperlipidemia by upregulating hepatic gluconeogenesis and impairing lipid deposition in adipose tissue.

Authors:  Vanessa P Houde; Sophie Brûlé; William T Festuccia; Pierre-Gilles Blanchard; Kerstin Bellmann; Yves Deshaies; André Marette
Journal:  Diabetes       Date:  2010-03-18       Impact factor: 9.461

10.  Glucose amplifies fatty acid-induced endoplasmic reticulum stress in pancreatic beta-cells via activation of mTORC1.

Authors:  Etti Bachar; Yafa Ariav; Mali Ketzinel-Gilad; Erol Cerasi; Nurit Kaiser; Gil Leibowitz
Journal:  PLoS One       Date:  2009-03-23       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.